陽光諾和(688621.SH):目前已有12款創新藥納入研發儲備
格隆匯12月19日丨陽光諾和(688621.SH)在投資者互動平台表示,公司主營業務聚焦於藥物研究服務領域,鑑於研究項目所處階段的不同,其執行週期存在差異。在項目推進過程中,公司遵循分階段收款的原則,並依據研發進展或最終成果的交付來確認收入,因此,本公司的業務本身並不具備季度週期性特點。 市場的短期波動並不能真實反映企業的內在價值。近年來,公司逐年加大對研發領域的投入,特別是在創新藥研發方面,通過自主研發與多方合作,公司不斷深化在鎮痛、腎病與透析、腫瘤輔助、心腦血管、抗菌用藥等核心領域的管線佈局。目前已有12款創新藥納入研發儲備,其中,“STC007注射液”研發進展迅速,已進入II期臨牀試驗階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.